Structural Basis for Antagonism by Suramin of Heparin Binding to Vaccinia Complement Protein
- U. of Cape Town
Suramin is a competitive inhibitor of heparin binding to many proteins, including viral envelope proteins, protein tyrosine phosphatases, and fibroblast growth factors (FGFs). It has been clinically evaluated as a potential therapeutic in treatment of cancers caused by unregulated angiogenesis, triggered by FGFs. Although it has shown clinical promise in treatment of several cancers, suramin has many undesirable side effects. There is currently no experimental structure that reveals the molecular interactions responsible for suramin inhibition of heparin binding, which could be of potential use in structure-assisted design of improved analogues of suramin. We report the structure of suramin, in complex with the heparin-binding site of vaccinia virus complement control protein (VCP), which interacts with heparin in a geometrically similar manner to many FGFs. The larger than anticipated flexibility of suramin manifested in this structure, and other details of VCP-suramin interactions, might provide useful structural information for interpreting interactions of suramin with many proteins.
- Research Organization:
- Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- USDOE
- OSTI ID:
- 1008551
- Journal Information:
- Biochemistry-US, Vol. 44, Issue (32) ; 08, 2005; ISSN 0006-2960
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
Suramin blocks interaction between human FGF1 and FGFR2 D2 domain and reduces downstream signaling activity
S100A13-C2A binary complex structure-a key component in the acidic fibroblast growth factor for the non-classical pathway